Journals / Viral Hepatitis Journal / 2014 / Cilt: 20 - Sayı: 2

Hepatit C Enfeksiyonu Olan Hastada Pegile İnterferon/Ribavirin+Telaprevir Tedavisi Sırasında Görülen Dermatolojik Yan Etki: Olgu Sunumu

Dermatological Side Effects in a Patient with Hepatitis C Infection During Treatment with Pegylated Interferon/ Ribavirin+Telaprevir: A Case Report

Pages
81–84
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result, with the advent of the new direct-acting antivirals, dermatological manifestations will be seen more frequently so patients should be monitored closely in terms of dermatological side effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic hepatitis C (HCV) and pegylated interferon (peg-IFN)/ribavirin (RBV) treatment dermotological side effects are well known.
📊
Key Findings & Data:New direct-acting antivirals have led to significant improvements in sustained virologic response rates, but several have led to an increase in dermatological side affects versus peg-IFN/RBV alone.
💡
Conclusion & Impact:As a result, with the advent of the new direct-acting antivirals, dermatological manifestations will be seen more frequently so patients should be monitored closely in terms of dermatological side effects.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Chronic hepatitis C (HCV) and pegylated interferon (peg-IFN)/ribavirin (RBV) treatment dermotological side effects are well known. New direct-acting antivirals have led to significant improvements in sustained virologic response rates, but several have led to an increase in dermatological side affects versus peg-IFN/RBV alone. A 55- year old man was administered peg-IFN alpha-2a 180 mcg/one times a week, RBV 1200 mg/day and telaprevir 2250mg/day with the diagnosis of chronic hepatitis C. Around the 8th week of the treatment the patient presented with itching eruptions on his face, neck, anterior wall of the and the forearm. A twelve administration of the combination therapy, the patient admitted to our hospital itching, rash, edema in whole body and facial edema and peeling in his facial skin. As a result, with the advent of the new direct-acting antivirals, dermatological manifestations will be seen more frequently so patients should be monitored closely in terms of dermatological side effects.

Özet

Hepatit C virüs (HCV) infeksiyonuna ve pegile interferon (peg-IFN)/ribavirin (RBV) tedavisine bağlı dermatolojik yan etkiler görülebilir. Yeni direkt etkili antiviraller kalıcı virolojik yanıt oranlarında önemli artışlara neden olmuştur, ancak yalnız peg-IFN/RBV tedavisine göre ise dermatolojik yan etkilerde artışa yol açmıştır. Elli beş yaşında erkek hastaya kronik hepatit C tanısıyla peg-IFN alfa-2a 180 mcg/haftada, RBV 1200 mg/gün ve telaprevir 2250 mg/gün tedavisi başlandı. Tedavinin sekinci haftasında hastanın yüzünde, boynunda, göğüs ön yüzünde ve ön kolda kaşıntılı erupsiyonlar oluştu. Hasta tedavinin 12. haftasında bütün vücutta kaşıntı, döküntü, facial ödem ve soyulma şikayetiyle hastaneye başvurdu. Sonuç olarak direk etkili antivirallerin dermatolojik yan etkileri çok daha sık görüldüğünden, bu hastaların dermatolojik yan etkiler açısından yakın takip edilmeleri gerekmektedir.

🔖

Cite This Article

SARI, T., KORUK, S. T., TEMOÇİN, F. (2014). Hepatit C Enfeksiyonu Olan Hastada Pegile İnterferon/Ribavirin+Telaprevir Tedavisi Sırasında Görülen Dermatolojik Yan Etki: Olgu Sunumu. Viral Hepatitis Journal, Cilt: 20 - Sayı: 2, 81–84. https://ajindex.com/articles/332718

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca S, et al. A Nationwide prevalence study and risk factors for hepatitis A, B, C and D infections in Turkey. Hepatology. 2010; 52(Suppl 1); 697
  2. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997; 26(Suppl 1): 112-21
  3. Charron A, Bessis D, Dereure O, Guilhou JJ, Guillot B. Local cutaneous side effects of interferons. Presse Med. 2001; 30: 1555-60
  4. Lubbe J. Dermatological side effects. Hot Topics in Viral Hepatitis. 2008; 9: 29-35
  5. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al; Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360: 1827-38
  6. Thompson A, Patel K, Tillman H, McHutchison JG. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol. 2009; 50: 184-94
  7. Sène D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis. 2004; 19(3-4): 357-81
  8. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010; 8(12): 1017-29
  9. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999; 42(10): 2204-12
  10. Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009; 23(10): 677-83
  11. Lang AM, Norland AM, Schuneman RL, Tope WD. Localized interferon alfa-2b-induced alopecia. Arch Dermatol. 1999; 135(9): 1126-8
  12. Dalmau J, Pimentel CL, Puig L, Peramiquel L, Roé E, Alomar A. Cutaneous necrosis after injection of polyethylene glycol- modified interferon alfa. J Am Acad Dermatol. 2005; 53(1): 62-6
  13. Lübbe J, Kerl K, Negro F, Saurat JH. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol. 2005; 153(5): 1088- 90
  14. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet. 1986; 1: 1466-8
  15. Fantini F, Padalino C, Gualdi G, Monari P, Giannetti A. Cutaneous lesions as initial signs of interferon alpha-induced sarcoidosis: report of three new cases and review of the literature. Dermatol Ther. 2009; 22(Sup